Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Finance
Biogen to slash over 1,000 jobs
by Laura Howes
July 28, 2023
| A version of this story appeared in
Volume 101, Issue 25
Biogen has announced a new plan it calls Fit for Growth, which will reduce its net operating expenses by about $700 million. Biogen plans to cut about 1,000 jobs—11% of its total—by 2025. In a press release, CEO Christopher A. Viehbacher describes the firm’s business as being “in transition.” Viehbacher joined the company to help it refocus after the failure of the Alzheimer’s disease drug Aduhelm.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X